Autoimmune Pancreatitis Drug Development

Creative Biolabs is a leading service company with a robust and standardized drug development platform, supporting clinical and preclinical research in the autoimmune field. We offer a full range of custom services (including monoclonal antibody development, bispecific antibody development, and cell-based therapy) for our customers all over the world.

Autoimmune pancreatitis is a rare form of chronic pancreatitis by an autoimmune inflammatory process. Autoimmune pancreatitis is clinically characterized by frequent presentation with obstructive jaundice with or without a pancreatic mass, histologically by a lymphoplasmacytic infiltrate and fibrosis. Clinically and histologically, it has two distinct subsets: (1) type 1 autoimmune pancreatitis, which is a systemic disease, and (2) type 2 autoimmune pancreatitis without systemic involvement. Now, autoimmune pancreatitis is accepted as a unique clinical entity that is present predominantly in the Asian population. Like other autoimmune diseases, autoimmune pancreatitis is frequently associated with rheumatoid arthritis, Sjogren’s syndrome, and inflammatory bowel disease.

Immunological interactions with autoimmune pancreatitis. Fig.1 Immunological interactions with autoimmune pancreatitis. (Hart, 2015)

Treatment of Autoimmune Pancreatitis

Although it is well established that spontaneous resolution can occur in most cases with autoimmune pancreatitis, symptomatic patients are best treated with corticosteroid therapy (i.e., prednisolone), which appeared to be a standard treatment. An initial prednisolone dose of 0.6 mg/kg/day is recommended, reduced to a maintenance dose over 3-6 months. However, maintenance treatment with low-dose steroids reduces but does not eliminate relapses.

While steroids are considered the mainstay of initial treatment, there is emerging evidence on the use of immunomodulators (including azathioprine, 6-mercaptopurine, and mycophenolate mofetil) as well as biological agents in maintaining remission in relapsing autoimmune pancreatitis. There is an FDA-approved chimeric monoclonal antibody against CD20 that can induce remission in autoimmune pancreatitis. In relapsing autoimmune pancreatitis, B-cell depletion therapy using anti-CD20 antibody is more efficient than immunomodulator drugs and shows better tolerance. Especially when glucocorticoid monotherapy ultimately fails to induce remission or control the disease and long-term toxicities pose a high risk to patients, the anti-CD20 antibody can induce remission.

Our Drug Development Services

Creative Biolabs is a dedicated provider that strives for the highest quality services for our global customers. With over a decade of experience and state-of-the-art drug development platforms, Creative Biolabs provides highly custom solutions to support your specific autoimmune pancreatitis drug development demands effectively. Different types of strategies are available at Creative Biolabs:

  • Monoclonal Antibody Development for autoimmune pancreatitis
  • Bispecific Antibody Development for autoimmune pancreatitis
  • Cell-based Therapy for autoimmune pancreatitis

As an experienced expert in drug development, Creative Biolabs provides comprehensive custom services to efficiently identify potential drugs of autoimmune diseases for our customers worldwide. Please feel free to send us your specific demands.


  1. Hart, P.A.; et al. Recent advances in autoimmune pancreatitis. Gastroenterology. 2015, 149(1): 39-51.

For Research Use Only | Not For Clinical Use

Online Inquiry

Autoimmune Diseases

We are dedicated to advancing and facilitating your drug development against autoimmune diseases

Contact us


  • Location:

  • Call:

  • Fax:

  • Email:


  • Location:

  • Call:

  • Email:

Autoimmune Diseases,Drug Development for
Autoimmune Diseases

Creative Biolabs is a world-leading CRO that is skilled in developing novel therapies,
especially in antibody and cell therapy for autoimmune diseases.

Copyright © 2023 Creative Biolabs. All Rights Reserved.